格隆汇2月2日丨一品红(300723.SZ)公布，截至2026年1月31日，公司通过回购专用证券账户以集中竞价 交易方式累计回购公司股份数量为277.34万股，占公司总股本的0.61%，最高成交价为37.85元/股，最低 成交价为32.15元/股，成交均价为34.95元/股，已使用资金总额为9,692.67万元（不含手续费）。公司上 述回购实施情况符合既定回购方案及相关法律法规的要求。 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）于 2025 年 12 月 15 日 召开第四届董事会第十四次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金及/或自筹资金以集中竞价方式回购公司部分已发行的人 民币普通股（A 股）股票用于维护公司价值及股东权益。 证券代码：300723 证券简称：一品红 公告编号：2026-007 一品红药业集团股份有限公司 关于回购公司股份的进展公告 本次用于回购的资金总额为不低于人民币 10,000 万元且不超过人民币 20,000 万元。回购价格不超过人民币 70.00 元/股（含）。回购股份的实施期限为 自公司董事会审议通过本次回购方案之日起三个月内。本次回购股份方案在董事 会决策权限之内，无需提交股东大会审议。具体情况详见公司分别于 2025 年 12 月 16 日、2025 年 12 月 17 日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《关于回购公司股份方案的公告》（公告编号：2025-089）、《回购报告书》（公告 ...

格隆汇2月2日丨一品红(300723.SZ)公布，截至2026年1月31日，公司通过回购专用证券账户以集中竞价 交易方式累计回购公司股份数量为277.34万股，占公司总股本的0.61%，最高成交价为37.85元/股，最低 成交价为32.15元/股，成交均价为34.95元/股，已使用资金总额为9,692.67万元（不含手续费）。公司上 述回购实施情况符合既定回购方案及相关法律法规的要求。 ...

证券代码：300723 证券简称：一品红 公告编号：2026-006 一品红药业集团股份有限公司 关于全资子公司获得阿仑膦酸钠口服溶液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于阿仑膦酸钠口服 溶液的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：阿仑膦酸钠口服溶液 英文名/拉丁名：Alendronate Sodium Oral Solution 主要成份：阿仑膦酸钠 剂 型：口服溶液剂 注册分类：化学药品 3 类 规 格：75ml:70mg（按 C4H13NO7P2计） 药品注册标准编号：YBH01152026 药品有效期：24 个月 申请事项：药品注册（境内生产） 包装规格： 1 瓶/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生 ...

（编辑 王雪儿） 证券日报网讯 1月29日，一品红在互动平台回答投资者提问时表示，公司是一家集药品研发、生产、销 售为一体的创新型生物医药企业，聚焦于儿童药和慢病药领域。公司始终坚持医药创新和高品质药品研 发。除了自主研发创新外，公司还通过合资合作，战略投资等多元开放的方式，布局公司未来可持续发 展创新产品。在儿童药领域，公司坚持以儿童临床需求为导向，采取自主研发与合作开发等模式相结 合，致力于儿童用药的全面技术创新，以提高儿童专用制剂的研发水平，研制口感佳、安全性高、剂量 精准的儿童药物，重点解决儿童用药依从性差、安全隐患多等临床难题。目前，公司着力打造儿童用药 特殊制剂创新研发基地，开发更多适合儿科患者的特殊专用制剂产品。 ...

格隆汇1月29日丨一品红(300723.SZ)在投资者互动平台表示，公司是一家集药品研发、生产、销售为一 体的创新型生物医药企业，聚焦于儿童药和慢病药领域。公司始终坚持医药创新和高品质药品研发。除 了自主研发创新外，公司还通过合资合作，战略投资等多元开放的方式，布局公司未来可持续发展创新 产品。 在儿童药领域，公司坚持以儿童临床需求为导向，采取自主研发与合作开发等模式相结合，致 力于儿童用药的全面技术创新，以提高儿童专用制剂的研发水平，研制口感佳、安全性高、剂量精准的 儿童药物，重点解决儿童用药依从性差、安全隐患多等临床难题。目前，公司着力打造儿童用药特殊制 剂创新研发基地，开发更多适合儿科患者的特殊专用制剂产品。 ...

Group 1 - Zhongyuan Expressway (600020) expects a net profit of approximately 612 million yuan for 2025, a decrease of about 30% year-on-year [1] - Bomin Electronics (603936) anticipates a net profit of 15 million to 22 million yuan for 2025, achieving a turnaround from loss to profit compared to the previous year [2] - Fangda Special Steel (600507) forecasts a net profit of 835 million to 998 million yuan for 2025, an increase of 236.9% to 302.67% year-on-year [3] Group 2 - Jiadu Technology (600728) expects a net profit of 160 million to 200 million yuan for 2025, recovering from a loss of 115 million yuan in the previous year [4] - Changyang Technology (688299) predicts a net loss of 116 million to 168 million yuan for 2025 [5] - Zhongzi Technology (688737) anticipates a net loss of 45.24 million to 67.86 million yuan for 2025 [6] Group 3 - Two-sided Needle (600249) expects a net profit of 5 million to 10 million yuan for 2025, a decline of 87.67% to 93.83% year-on-year [7] - Sanrenxing (605168) forecasts a net profit of 181 million to 209 million yuan for 2025, an increase of 46.79% to 69.5% year-on-year [8] - Shubeide (300322) anticipates a net profit of 60 million to 70 million yuan for 2025, recovering from a loss of 64.46 million yuan in the previous year [9] Group 4 - Maoye Commercial (600828) expects a net loss of 201 million to 242 million yuan for 2025 [10] - Hongsheng Huayuan (601096) forecasts a net profit of 348 million to 400 million yuan for 2025, an increase of 51.22% to 73.82% year-on-year [11] - Huafeng Technology (688629) anticipates a net profit of 338 million to 388 million yuan for 2025, achieving a turnaround from loss to profit [12] Group 5 - Aerospace Rainbow (002389) expects a net profit of 25 million to 31 million yuan for 2025, a decrease of 64.84% to 71.65% year-on-year [14] - Shangong Shenbei (600843) predicts a net loss of 120 million to 150 million yuan for 2025, compared to a loss of 244 million yuan in the previous year [15] - Chaoxun Communication (603322) anticipates a net profit of 36 million to 54 million yuan for 2025, achieving a turnaround from loss to profit [16] Group 6 - Guannong Co. (600251) expects a net profit of 330 million to 340 million yuan for 2025, an increase of 61.29% to 66.18% year-on-year [17] - Shandong Steel (600022) forecasts a net profit of around 100 million yuan for 2025, recovering from a loss of 2.891 billion yuan in the previous year [18] - Baili Technology (603959) anticipates a net loss of 140 million to 200 million yuan for 2025 [19] Group 7 - Electric Power Investment Hydropower (600292) expects a net profit of approximately 517 million yuan for 2025, a year-on-year increase of about 1337% [20] - Aibulu (301259) forecasts a net profit of 26 million to 33.8 million yuan for 2025, recovering from a loss of 30.84 million yuan in the previous year [21] - Yipin Hong (300723) announced that its subsidiary received approval for clinical trials of a new drug [22] Group 8 - Meixin Sheng (688458) plans to acquire 100% equity of Xinyan Micro for 160 million yuan [23][24] - Lanshi Heavy Industry (603169) expects a net loss of 370 million to 440 million yuan for 2025, transitioning from profit to loss [25] - Hongyang (000525) anticipates a net loss of 260 million to 390 million yuan for 2025, compared to a profit of 388 million yuan in the previous year [26] Group 9 - Tianzhihang (688277) predicts a net loss of 165 million to 198 million yuan for 2025, with losses expected to widen by 36.22% to 63.46% compared to the previous year [27] - Tongda Co. (002560) announced plans for a major shareholder to reduce holdings by no more than 1% [28] - *ST Chengchang (001270) expects a net profit of 95 million to 124 million yuan for 2025, recovering from a loss of 31.12 million yuan in the previous year [29] Group 10 - Yirui Technology (688301) reported a net profit of 661 million yuan for 2025, a year-on-year increase of 42.15% [30] - Hualitai (001217) anticipates a net loss of 28 million to 38 million yuan for 2025, transitioning from profit to loss [31] - Yunjiji Group (001288) expects a net profit of 220 million to 252 million yuan for 2025, a year-on-year increase of 40% to 60% [32] Group 11 - Heertai (002402) forecasts a net profit of 638 million to 729 million yuan for 2025, an increase of 75% to 100% year-on-year [33] - Shenhao Technology (300853) anticipates a net loss of 185 million to 220 million yuan for 2025, compared to a loss of 238 million yuan in the previous year [34] - Zhongyan Dadi (003001) expects a net profit of 10 million to 15 million yuan for 2025, a decline of 75.97% to 83.98% year-on-year [35] Group 12 - Landai Technology (002765) forecasts a net profit of 180 million to 200 million yuan for 2025, a year-on-year increase of 44.83% to 60.93%, with a non-recurring profit of 140 million to 160 million yuan, an increase of 113.1% to 143.54% [37] - Yingfeite (300582) plans to raise product prices by 5% to 15% starting March 1, 2026, due to rising raw material costs [38] - Lanzhou Bank (001227) plans to distribute 285 million yuan in cash dividends for the 2025 interim profit distribution [39] Group 13 - Wancheng Group (300972) announced plans for shareholders to reduce holdings by no more than 1.27% [40] - *ST Huarong (600421) expects to turn a profit in 2025, with a projected net profit of 6.5 million to 8 million yuan [41] - Jiaheng Home (300955) anticipates a net loss of 29 million to 39 million yuan for 2025, compared to a loss of 23.69 million yuan in the previous year [42] Group 14 - Aide Biology (300685) announced plans for a major shareholder to reduce holdings by no more than 1.22% [43] - Haixia Innovation (300300) expects a net profit of 100 million to 150 million yuan for 2025, a year-on-year increase of 1660.56% to 2540.85% [44]

Core Viewpoint - Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for clinical trials of its product, Qinxiang Qingjie Oral Liquid, aimed at treating acute upper respiratory infections in adults [1] Group 1: Company Developments - Yipinhong's wholly-owned subsidiary, Yipinhong Biopharmaceutical Co., Ltd., has submitted an application for Qinxiang Qingjie Oral Liquid, which has now been accepted for clinical trials [1] - The approval notification number for the clinical trial is 2026LP00262, indicating formal recognition by regulatory authorities [1] Group 2: Industry Context - The clinical trial is focused on a specific indication, namely acute upper respiratory infections with both heat syndrome, highlighting the company's targeted approach in the biopharmaceutical sector [1]

证券日报网讯1月28日，一品红（300723）在互动平台回答投资者提问时表示，一品红是一家集药品研 发、生产、销售为一体的创新型生物医药企业，聚焦于儿童药和慢病药领域；目前，公司具备医药全产 业链的研发运营管理能力，产品涵盖范围包括化学药(含制剂和原料药)、中(成)药等领域。 ...

Core Viewpoint - The announcement indicates that Yipinhong's subsidiary, Yipinhong Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of Qinxiangqing Jie Oral Solution, aimed at treating acute upper respiratory infections in adults with specific symptoms [1]. Group 1 - Yipinhong's subsidiary has been granted a clinical trial approval for Qinxiangqing Jie Oral Solution [1]. - The clinical trial will focus on adults suffering from acute upper respiratory infections characterized by both internal and external heat symptoms [1]. - The application for the clinical trial was a supplementary submission aimed at refining the clinical trial protocol and expanding the target population [1].